Your clinical team can personalize injection timing based on your daily routine and how your body responds to the medication
2 Monotherapy is no longer available in the USA since Jan 2023, and lixisenatide-glargine (iGlarLixi) has been approved for type 2 diabetes
We perform comprehensive initial assessments, including in-house lab work and metabolic testing, to understand your unique metabolic profile
Timmerman LA, Holton T, Yuneva M, Louie RJ, Padr M, Daemen A, Hu M, Chan DA, Ethier SP, van't Veer LJ, Polyak K, McCormick F, Gray JW
Understanding these distinctions is the difference between making an informed decision and being surprised after purchase
of this final rule with comment period)